Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;9(4):503-12.
doi: 10.1177/1756283X16647935. Epub 2016 May 19.

The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes

Gionata Fiorino  1 , Daniela Gilardi  1 , Silvio Danese  2
Affiliations
Review

The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes

Gionata Fiorino et al. Therap Adv Gastroenterol. 2016 Jul.

Abstract

Antiadhesion molecules are effective and safe in patients with ulcerative colitis (UC). Etrolizumab, a monoclonal antibody targeting both α4β7 and αEβ7, represents a promising therapy for patients with UC, since this novel mechanism of action may be effective in blocking leukocyte recruitment both at the vascular and at the mucosal level. Preliminary studies show that etrolizumab is effective in inducing clinical response and remission, and mucosal healing. Moreover, new predictors of response have recently been identified, opening the way to a tailored therapeutic approach. This review of the literature aims to present and discuss the most recent evidence on etrolizumab in UC, focusing on the clinical implications of the use of etrolizumab in UC.

Keywords: anti-integrins; etrolizumab; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Mechanism of action of etrolizumab. Like the other antiadhesion molecules, etrolizumab blocks α4β7 integrin at the endothelial level, but it has a peculiar action as a blocker of αE integrin interaction with epithelial cells, thus also controlling inflammation at the mucosal level.
See this image and copyright information in PMC

References

    1. Barczyk M., Carracedo S., Gullberg D. (2010) Integrins. Cell Tissue Res 339: 269–280. - PMC - PubMed
    1. Bravatà I., Allocca M., Fiorino G., Danese S. (2015) Integrins and adhesion molecules as targets to treat inflammatory bowel disease. Curr Opin Pharmacol 25: 67–71. - PubMed
    1. Cepek K., Parker C., Madara J., Brenner M. (1993) Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 150: 3459–3470. - PubMed
    1. Cesarini M., Fiorino G. (2013) Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an update. Expert Rev Clin Immunol 9: 301–306. - PubMed
    1. Colombel J., Sandborn W., Reinisch W., Mantzaris G., Kornbluth A., Rachmilewitz D., et al. (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362: 1383–1395. - PubMed

LinkOut - more resources